Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Hepatocyte growth factor receptor
Synonyms [1]

MET (MET proto-oncogene, receptor tyrosine kinase) encodes the hepatocyte growth factor receptor protein. Germline mutations in the tyrosine kinase domain of MET occur in 100% of hereditary papillary renal cell carcinoma (PMID: 9140397). Somatic MET mutations and/or amplifications have been observed in sporadic papillary renal cell carcinoma, head and neck squamous cell carcinoma (PMID: 10734314), childhood hepatocellular carcinoma (PMID: 9927037), lung cancer (PMID: 14559814; PMID: 17463250), gastric cancer (PMID: 10223227), esophageal cancer (PMID: 16186806), colorectal cancer (PMID: 10343196), gliomas (PMID: 18077431), and clear cell ovarian cancer (PMID: 21478826). In the context of malignancy, aberrant signaling through the MET receptor promotes pleiotrophic effects including growth, survival, invasion, migration, angiogenesis and metastasis (Birchmeier et al. 2003; Peruzzi and Bottaro 2006).

MET is altered in 2.60% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

MET GENIE Cases - Top Diseases

The most common alterations in MET are MET Mutation (1.90%), MET Amplification (0.69%), MET Exon 14 Mutation (0.23%), MET c.1078-c.1345 Missense (0.15%), and MET X1010_splice (0.13%) [3].

MET GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of MET in Diseases

Non-Small Cell Lung Carcinoma +

Malignant Solid Tumor +

Breast Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Colorectal Carcinoma +

Hepatocellular Carcinoma +

Melanoma +

Gastric Adenocarcinoma +

Gastric Carcinoma +

Squamous Cell Lung Carcinoma +

Cancer +

Glioblastoma +

Head And Neck Squamous Cell Carcinoma +

Bladder Carcinoma +

Head And Neck Carcinoma +

Lymphoma +

Prostate Carcinoma +

Endometrial Carcinoma +

Renal Cell Carcinoma +

Urothelial Carcinoma +

Colorectal Adenocarcinoma +

Ovarian Carcinoma +

Soft Tissue Sarcoma +

Multiple Myeloma +

Pancreatic Adenocarcinoma +

Pancreatic Carcinoma +

Papillary Renal Cell Carcinoma +

Malignant Uterine Neoplasm +

Esophageal Carcinoma +

Non-Squamous Non-Small Cell Lung Carcinoma +

Mucosal Melanoma +

Lung Carcinoma +

Lung Adenocarcinoma +

Rhabdomyosarcoma +

Cervical Squamous Cell Carcinoma +

Glioma +

Cervical Carcinoma +

Small Intestinal Adenocarcinoma +

Anaplastic Astrocytoma +

Gliosarcoma +

Esophageal Squamous Cell Carcinoma +

Bile Duct Carcinoma +

Cholangiocarcinoma +

Gallbladder Carcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Medulloblastoma +

Ewing Sarcoma +

Mesothelioma +

Sarcoma +

B-Cell Non-Hodgkin Lymphoma +

Osteosarcoma +

Thyroid Gland Medullary Carcinoma +

Adrenal Cortex Carcinoma +

Alveolar Soft Part Sarcoma +

Bronchogenic Carcinoma +

Clear Cell Sarcoma Of Soft Tissue +

Diffuse Intrinsic Pontine Glioma +

Hepatoblastoma +

Wilms Tumor +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.